Michael Han, MD
Internal Medicine · Birmingham, ALNPI 1477528545
Payments from drug & device makers
Across 590 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Novo Nordisk$2K
- Pfizer$1K
- Lilly USA, LLC$1K
- Sanofi US Services Inc.$1K
- Bayer$846
- plus $3K from 32 others
Across 1 payment — averaging $1165.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $7,096 |
| Novo Nordisk | 128 | $2,208 |
| Pfizer | 78 | $1,401 |
| Lilly USA, LLC | 77 | $1,266 |
| Sanofi US Services Inc. | 1 | $1,000 |
| Bayer | 44 | $846 |
| Boehringer Ingelheim | 50 | $716 |
| AbbVie(2 entities) | 36 | $520 |
| Johnson & Johnson | 24 | $362 |
| Amgen(2 entities) | 16 | $262 |
| Daiichi Sankyo Inc. | 6 | $203 |
| Amarin Pharma, Inc. | 18 | $190 |
| Novartis | 7 | $158 |
| Merck | 9 | $157 |
| GSK | 9 | $154 |
| Exact Sciences | 5 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Astellas Pharma US Inc | 3 | $42 |
| Radius Health, Inc. | 3 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Endogastric Solutions, Inc | 1 | $30 |
| Vivus LLC | 2 | $26 |
| BETA Bionics, Inc. | 1 | $24 |
| Soleno Therapeutics, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Abbott | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
How this compares
$17,307 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.